WHO Issues New Guideline to Expand Global Access to Controlled Medications
WHO Launches Landmark Guideline to Bridge Global Gaps in Access to Controlled Medicines In a bold step toward improving global health equity, the World Health Organization (WHO) unveiled a new…
China Approves In-House Anti-Insomnia Drug DAYVIGO
Eisai’s Lemborexant (DAYVIGO®) Receives Regulatory Approval in China for the Treatment of Insomnia Eisai Co., Ltd., a leading global pharmaceutical company headquartered in Tokyo and led by CEO Haruo Naito,…
Advancing the Future of Care with Pompe Patients
Partnering for Progress: How Astellas and the Pompe Disease Community Are Shaping the Future Together Pompe disease is a rare, inherited, and progressively debilitating disorder that profoundly affects the lives…
Driving Change in Oncology: Pivotal Data and Global Trends at #ASCO25
Practice-Changing Data, Innovative Modalities, and Global Impact Headline ASCO 2025 The oncology community is converging in Chicago this week for the highly anticipated 2025 Annual Meeting of the American Society…
4 Biotech Firms Face Hurdles Amid a Shifting COVID-19 Vaccine Landscape
U.S. Vaccine Innovation at Risk: How Four Biotechs Are Being Squeezed by Shifting Policies, Funding Cuts, and Regulatory Changes As the World Health Organization (WHO) sets a new course for…
World Health Assembly Extends Global Digital Health Strategy to 2027, Approves 2028–2033 Phase
World Health Assembly Approves Extension of Global Digital Health Strategy to 2027 and Greenlights Next Phase for 2028–2033 In a landmark decision underscoring the accelerating global commitment to digital health,…
Cullinan, Taiho to Present Positive Zipalertinib Phase 2b Results at ASCO 2025
Cullinan Therapeutics and Taiho Highlight Promising Phase 2b Results of Zipalertinib in Advanced EGFR ex20ins NSCLC at ASCO 2025 Cullinan Therapeutics,in collaboration with Taiho Pharmaceutical Co., Ltd., and its U.S.…
XTANDI Delivers Long-Term Survival in Metastatic Hormone-Sensitive Prostate Cancer
Astellas and Pfizer Showcase Five-Year Survival Benefits of XTANDI in Metastatic Hormone-Sensitive Prostate Cancer at ASCO 2025 In a pivotal milestone for prostate cancer treatment, Astellas Pharma Inc. and Pfizer…
Walgreens Clinical Trials: 3 Strategies for Patient-Centered Engagement
Bringing Research to the People: How Walgreens Clinical Trials is Revolutionizing Patient Engagement Over the past three years, Walgreens has made remarkable strides in democratizing access to clinical trials. Through…
Court Blocks HHS Layoff and Restructuring Plans, Citing Overreach of Authority
Federal Judge Blocks Trump Administration’s Sweeping HHS Layoff and Reorganization Plan, Citing Lack of Legal Authority A federal judge in California has issued a significant legal blow to the Trump…
EU Recommends Approval of Eylea™ 8 mg with Extended 6-Month Dosing Interval
Bayer’s Eylea™ 8 mg Recommended for EU Approval with Extended 6-Month Treatment Interval for Major Retinal Diseases Bayer has today announced a significant milestone in the treatment of retinal diseases,…
CHMP Backs Blenrep Combos for Relapsed/Refractory Multiple Myeloma
GSK’s Blenrep Combinations Receive Positive CHMP Opinion for Relapsed or Refractory Multiple Myeloma, Signaling Expanded Access Across Europe In a significant step forward for the treatment of multiple myeloma, GSK…